The disease is driven by complex combinations of multiple genetic mutations rather than a single defect, which Somedeb Ball, MBBS, Assistant Professor of Medicine in Hematology/Oncology at Vanderbilt-Ingram Cancer Center, is studying.
Department of Medicine faculty Tuya Pal, MD, and Ben Ho Park, MD, PhD, were among those awarded grants by Susan G. Komen, the internationally known nonprofit breast cancer organization.
Douglas Johnson, MD, MSCI, professor of Medicine, has been named associate director for Translational Research.
Early clinical research by Vanderbilt Health and Cumberland Pharmaceuticals Inc. suggests that an investigational drug originally developed to treat cardiovascular disease may reduce the risk of metastasis — or spread — of breast, lung and other solid tumors.
This minimally invasive and cost-effective alternative to tissue biopsy offers “an accessible tool for tailoring treatment strategies in breast cancer,” researchers, including Justin Balko, PhD, PharmD, reported April 22 in the journal Science Translational Medicine.
The findings were reported March 19 in the Nature partner journal npj Breast Cancer; the paper’s corresponding author is Sonya Reid, MD, MPH, associate professor of Medicine at Vanderbilt Health.
Mohamed Shanshal, MD, and Fabien Maldonado, MD, faculty members in the Department of Medicine, were integral members of the treatment team.
Vanderbilt-Ingram Cancer Center has treated its first patient in a newly launched therapy program that magnifies the power of a person’s natural defense system against tumors.
Hematologists with Vanderbilt-Ingram Cancer Center have published strategies for implementing outpatient treatment programs for bispecific antibodies, an immunotherapy that can cause adverse reactions.
